217 related articles for article (PubMed ID: 30940667)
1. Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS).
Benger M; Vink J; Snell LB; Breen K
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30940667
[TBL] [Abstract][Full Text] [Related]
2. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.
Dufrost V; Risse J; Zuily S; Wahl D
Curr Rheumatol Rep; 2016 Dec; 18(12):74. PubMed ID: 27812956
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome.
Liu A; Rupani KV; Naymagon L
Eur J Haematol; 2022 Jul; 109(1):69-74. PubMed ID: 35305281
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Pengo V; Denas G; Zoppellaro G; Jose SP; Hoxha A; Ruffatti A; Andreoli L; Tincani A; Cenci C; Prisco D; Fierro T; Gresele P; Cafolla A; De Micheli V; Ghirarduzzi A; Tosetto A; Falanga A; Martinelli I; Testa S; Barcellona D; Gerosa M; Banzato A
Blood; 2018 Sep; 132(13):1365-1371. PubMed ID: 30002145
[TBL] [Abstract][Full Text] [Related]
5. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Malec K; Góralczyk T; Undas A
Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
Cohen H; Doré CJ; Clawson S; Hunt BJ; Isenberg D; Khamashta M; Muirhead N;
Lupus; 2015 Sep; 24(10):1087-94. PubMed ID: 25940537
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
Resseguier AS; Pereira B; Rieu V; Le Guenno G; Grobost V; Ruivard M
Lupus; 2017 Oct; 26(12):1297-1303. PubMed ID: 28355988
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
Cohen H; Hunt BJ; Efthymiou M; Arachchillage DR; Mackie IJ; Clawson S; Sylvestre Y; Machin SJ; Bertolaccini ML; Ruiz-Castellano M; Muirhead N; Doré CJ; Khamashta M; Isenberg DA;
Lancet Haematol; 2016 Sep; 3(9):e426-36. PubMed ID: 27570089
[TBL] [Abstract][Full Text] [Related]
9. Direct oral anticoagulants in antiphospholipid syndrome: a real life case series.
Betancur JF; Bonilla-Abadía F; Hormaza AA; Jaramillo FJ; Cañas CA; Tobón GJ
Lupus; 2016 May; 25(6):658-62. PubMed ID: 26743321
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
[TBL] [Abstract][Full Text] [Related]
11. Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review.
Girón-Ortega JA; Girón-González JA
Med Clin (Barc); 2023 Jul; 161(2):65-77. PubMed ID: 37105842
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Bauersachs R; Schellong S; Stücker M; Oldenburg J; Kalka C; Scholz U; Lindhoff-Last E
Hamostaseologie; 2019 Aug; 39(3):298-300. PubMed ID: 31404932
[No Abstract] [Full Text] [Related]
13. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
Ann Intern Med; 2019 Nov; 171(10):. PubMed ID: 31610579
[No Abstract] [Full Text] [Related]
14. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
Ordi-Ros J; Sáez-Comet L; Pérez-Conesa M; Vidal X; Riera-Mestre A; Castro-Salomó A; Cuquet-Pedragosa J; Ortiz-Santamaria V; Mauri-Plana M; Solé C; Cortés-Hernández J
Ann Intern Med; 2019 Nov; 171(10):685-694. PubMed ID: 31610549
[TBL] [Abstract][Full Text] [Related]
15. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study.
Malec K; Broniatowska E; Undas A
Lupus; 2020 Jan; 29(1):37-44. PubMed ID: 31757182
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
[TBL] [Abstract][Full Text] [Related]
17. Would you use novel oral anticoagulants (NOACs) for thromboprophylaxis in patients with an underlying hypercoagulable state? A literature review through a case report.
Kakadia B; Suero-Abreu GA; Daci R; Then RK
BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33127703
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
19. Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study.
Sato T; Nakamura H; Fujieda Y; Ohnishi N; Abe N; Kono M; Kato M; Oku K; Bohgaki T; Amengual O; Yasuda S; Atsumi T
Lupus; 2019 Nov; 28(13):1577-1582. PubMed ID: 31635559
[TBL] [Abstract][Full Text] [Related]
20. Use of direct oral anticoagulants in antiphospholipid syndrome.
Cohen H; Efthymiou M; Isenberg DA
J Thromb Haemost; 2018 Jun; 16(6):1028-1039. PubMed ID: 29624847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
